HilleVax, Inc. (HLVX)

NASDAQ: HLVX · IEX Real-Time Price · USD
18.07
+0.80 (4.63%)
Feb 6, 2023, 1:45 PM EST - Market open
4.63%
Market Cap 606.88M
Revenue (ttm) n/a
Net Income (ttm) -175.95M
Shares Out 33.35M
EPS (ttm) -27.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,587
Open 16.91
Previous Close 17.27
Day's Range 16.91 - 18.26
52-Week Range 7.90 - 24.42
Beta n/a
Analysts Buy
Price Target 35.36 (+95.68%)
Earnings Date n/a

About HLVX

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2022
Employees 15
Stock Exchange NASDAQ
Ticker Symbol HLVX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for HLVX stock is "Buy." The 12-month stock price forecast is $35.36, which is an increase of 95.68% from the latest price.

Price Target
$35.36
(95.68% upside)
Analyst Consensus: Buy
Stock Forecasts

News

HilleVax Announces Executive Management Appointments and Promotions

BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appoin...

1 month ago - GlobeNewsWire

HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it wi...

1 month ago - GlobeNewsWire

After Plunging 32.4% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax, Inc. (HLVX)

HilleVax, Inc. (HLVX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings esti...

1 month ago - Zacks Investment Research

Down 25.2% in 4 Weeks, Here's Why You Should You Buy the Dip in HilleVax, Inc. (HLVX)

HilleVax, Inc. (HLVX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev...

1 month ago - Zacks Investment Research

HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results fro...

2 months ago - GlobeNewsWire

Here's Why "Trend" Investors Would Love Betting on HilleVax, Inc. (HLVX)

HilleVax, Inc. (HLVX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it throu...

2 months ago - Zacks Investment Research

Wall Street Analysts Predict a 67% Upside in HilleVax, Inc. (HLVX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 67% in HilleVax, Inc. (HLVX). While the effectiveness of this highly sought-after metric is questionable, the p...

2 months ago - Zacks Investment Research

HilleVax to Participate in November Investor Conferences

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it wi...

3 months ago - GlobeNewsWire

HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it w...

5 months ago - GlobeNewsWire

HilleVax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum

BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it wi...

6 months ago - GlobeNewsWire

HilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

BOSTON, Aug. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial r...

6 months ago - GlobeNewsWire

HilleVax Announces Results from 5-Year Clinical Study Supporting Long-Term Immunogenicity of HIL-214 Norovirus Vaccine Candidate

Pan-Ig and HBGA blocking antibody responses persisted to year 5

7 months ago - GlobeNewsWire

Biotech Public Offerings at 10-Year Low

No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerin...

Other symbols: BLTEPEPGTAKXBI
7 months ago - GuruFocus

HilleVax Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Initiated Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants (NOR-212)

8 months ago - GlobeNewsWire